BRAF and melanoma: In our initial screen we profiled the NCATS Mechanism Interrogation Plate (MIPe) library of 1910 compounds (24) against a pair of matched isogenic parental and BRAFi-resistant melanoma cells, UACC62P which harbors the BRAFV600E oncogene and its resistant counterpart UACC62R which was developed by in vitro selection with vemurafenib and is resistant to multiple BRAF inhibitors, including dabrafenib and encorafenib (23).